Pharmaceutical company Bristol-Myers Squibb will be creating up to 400 manufacturing jobs at its newly planned large-scale biologics facility in Cruiserath, Dublin.
Construction plans were announced this morning, which will see a further 1,000 short-term jobs also created as part of the project.
The new facility will produce multiple therapies for the company’s growing biologics portfolio, significantly increasing Bristol-Myers Squibb’s biologics manufacturing capacity while playing a central role in its global manufacturing network.
“Our investment in this new facility reflects the strength of our business and the increasingly important role that biologic medicines will play in Bristol-Myers Squibb’s future,” said Lamberto Andreotti, chief executive officer of Bristol-Myers Squibb.
“For 50 years, Bristol-Myers Squibb has maintained a significant manufacturing presence in Ireland, and we look forward to building on that legacy through this significant expansion of our manufacturing capability.”
Significant investment in Ireland
The US company has approved the first stage of funding for the project, with the full cost expected to be comparable to the roughly US$900m investment to construct a similar facility in Devens, Massachusetts.
About 350 to 400 scientists, engineers, bioprocess operators, quality specialists and other skilled professionals are expected to work at the Dublin facility when construction is finished.
The completion of the Dublin facility, including commissioning and validation, is expected to take about four years and is estimated to be operational in 2019.
“This is fantastic news for Dublin and indeed for Ireland and signals the confidence that Bristol-Myers Squibb has in this country,” said Ged Nash, Minister for Business and Employment.
